A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab™ for pre-exposure use in healthy adults: Results from a randomized controlled phase-II trial

Vaccine

Volumn 31, Issue 18, 2013, Pages 2295-2301

  Pichon, Sylvie ^a   Guinet Morlot, Françoise ^a   Minutello, Maria ^a   Donazzolo, Yves ^b   Rouzier, Regine ^c   Chassard, Didier ^d   Fitoussi, Serge ^e   Hou, Victor ^a  

^a SANOFI PASTEUR   (France)

^b Eurofins Medinet Inc   (Germany)

^c Centre CAP   (France)

^d Biotrial   (France)

^e MEDISCIS   (France)

Author keywords

Clinical trial; Immunogenicity; Pre exposure prophylaxis; Rabies; Rabies vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; NEXT GENERATION PURIFIED VERO CELL RABIES VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; APPLICATION SITE PAPULE; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; EXPOSURE; FEMALE; FRANCE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE REACTION; LUNG EMBOLISM; MALE; NONHUMAN; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RABIES; RABIES VIRUS; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VERO CELL;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; FEMALE; FRANCE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; RABIES; RABIES VACCINES; RABIES VIRUS; VERO CELLS; YOUNG ADULT;

EID: 84875824668     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.058     Document Type: Article

References (18)

1. Jackson A.C. Human disease. Rabies 2007, Elsevier, London. 2nd ed. A.C. Jackson, A.H. Wunner (Eds.).
2. Plotkin SA. Rabies clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2000;30(January (1)):4-12.
3. Feder H.M., Petersen B.W., Robertson K.L., Rupprecht C.E. Rabies: still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts. Curr Infect Dis Rep 2012, 14(August (4)):408-422.
4. Bourhy H., Dautry-Varsat A., Hotez P.J., Salomon J. Rabies, still neglected after 125 years of vaccination. PLoS Negl Trop Dis 2010, 4(11):e839.
5. WHO. WHO Expert Consultation on rabies. First Report. Geneva, Switzerland: World Health Organization; 2004.
6. Dodet B. Report of the fifth AREB meeting Ho Chi Minh City, Vietnam, 17-20 November 2008. Vaccine 2009, 27(April (18)):2403-2407.
7. Dodet B., Adjogoua E.V., Aguemon A.R., Amadou O.H., Atipo A.L., Baba B.A., et al. Fighting rabies in Africa: the Africa Rabies Expert Bureau (AfroREB). Vaccine 2008, 26(November (50)):6295-6298.
8. Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, et al. Human rabies prevention - United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control 2008;57(May (RR-3)):1-28.
9. WHO Rabies vaccines: WHO position paper - recommendations. Vaccine 2010, 28(44):7140-7142.
10. Dreesen D.W. A global review of rabies vaccines for human use. Vaccine 1997, 15(Suppl. Spring):S2-S6.
11. Toovey S. Preventing rabies with the Verorab vaccine: 1985-2005. Twenty years of clinical experience. Travel Med Infect Dis 2007, 5(November (6)):327-348.
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Q5E: comparability of biotechnological/biological products subject to changes in their manufacturing process. 2005.
13. European Department for the Quality of Medicines within the Council of Europe European pharmacopoeia 2005, Council of Europe, Strasbourg. 7th ed.
14. Farrington C.P., Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990, 9(December (12)):1447-1454.
15. Smith J.S., Yager P.A., Baer G.M. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Org 1973, 48(May (5)):535-541.
16. Plotkin S.A., Ruprecht C.E., Koprowski H. Chapter 37 rabies vaccine. Vaccines 2004, Elsevier, Philadephia. 4th ed. S.A. Plotkin, W. Orenstein (Eds.).
17. Mclean H.Q., WHO The immunological basis for immunization series: module 17: rabies 2011, 24. World Health Organisation, Geneva, Switzerland. World Health Organisation (Ed.).
18. Kopel E., Oren G., Sidi Y., David D. Inadequate antibody response to rabies vaccine in immunocompromised patient. Emerg Infect Dis 2012, 18(September (9)):1493-1495.